Protea Biosciences Group, Inc. announced today that Greg Kilby, Ph.D. has joined the Company as its chief bioanalytics officer (CBO) and director of Biomolecular Information Services. Prior to joining Protea, Kilby held the position of director, North America Life Sciences Mass Spectrometry Application and Demonstration Laboratories for Thermo Fisher Scientific and previously held positions at Agilent Technologies, Inc. and Pfizer, Inc.
“We are delighted to have Greg join our team here at Protea,” says Steve Turner, Protea’s CEO. “With the demand we are experiencing for our biomolecular information services, we are expanding our capabilities. Dr. Kilby’s extensive knowledge and experience will help assure we achieve our growth objectives for our molecular information business.”
Under Dr. Kilby’s leadership, Protea has acquired and installed a Bruker UltrafleXtreme MALDI TOF/TOF mass spectrometer to expand the Company’s capabilities in mass spectrometry imaging for large molecules, to complement its existing mass spectrometry imaging capabilities via its proprietary LAESI technology.
In addition, Protea has hired Erin Seeley, Ph.D., Senior Lead Scientist, Mass Spectrometry Imaging. Prior to joining Protea, Seeley was associate director of the Tissue Imaging Core Laboratory at Vanderbilt University.
“Mass spectrometry imaging has significant potential to impact many fields of scientific endeavor, ranging from agriculture to clinical,” says Kilby. “It is exciting to join an organization that is rapidly establishing commercial leadership in this emerging field and to explore and commercialize novel ways of approaching very challenging science and biology by blending established bioanalytical technologies with mass spectrometry imaging. I am pleased to work with this outstanding team, and I look forward to contributing to the future growth and success of Protea Biosciences.”
